Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth

Jin Soo Kim, Dennis R. Taaffe, Daniel A. Galvão, Nicolas H. Hart, Elin Gray, Charles J. Ryan, Stacey A. Kenfield, Fred Saad, Robert U. Newton

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Background: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. Methods: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. Results: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). Conclusion: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)86-92
Number of pages7
JournalProstate Cancer and Prostatic Diseases
Issue number1
StatePublished - Mar 2022

Bibliographical note

Funding Information:
This work was funded by the Movember Foundation. National Health and Medical Research Council Centre of Research Excellence (NHMRC-CRE; APP1116334) funded the additional materials involving serum analysis and cell work through Centre for Research Excellence in Prostate Cancer Survivorship. J-S.K is supported by the NHMRC Centre for Research Excellence in Prostate Cancer Survivorship Scholarship. Open Access funding enabled and organized by CAUL and its Member Institutions.

Funding Information:
The authors thank Harry Perkins Institute, Nedlands, WA, Australia, for providing prostate cancer cell line DU145.

Publisher Copyright:
© 2022, The Author(s).


  • Aged
  • Aged, 80 and over
  • Body Composition
  • Cell Proliferation
  • Exercise
  • Exercise Therapy
  • Humans
  • Male
  • Prostatic Neoplasms/pathology
  • Prostatic Neoplasms, Castration-Resistant/therapy

PubMed: MeSH publication types

  • Journal Article
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't


Dive into the research topics of 'Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth'. Together they form a unique fingerprint.

Cite this